Stockscreener 앱 받기
1.36
3.55%
-0.05
시간 외 거래:
1.35
-0.01
-0.74%
전일 마감가:
$1.41
열려 있는:
$1.43
하루 거래량:
382.81K
Relative Volume:
0.45
시가총액:
$31.26M
수익:
-
순이익/손실:
$-8.09M
주가수익비율:
-3.1236
EPS:
-0.4354
순현금흐름:
$-7.37M
1주 성능:
-2.86%
1개월 성능:
-8.11%
6개월 성능:
+5.43%
1년 성능:
-6.21%
1일 변동 폭
$1.3001
$1.43
1주일 범위
$1.22
$1.4399
52주 변동 폭
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
명칭
NanoViricides Inc
전화
203-937-6137
주소
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.36 | 32.41M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | Alliance Global Partners | Buy |
| 2015-02-11 | 개시 | Midtown Partners | Strong Buy |
NanoViricides Inc 주식(NNVC)의 최신 뉴스
NanoViricides Receives DRC Approval to Advance Phase II Ebola Trial for Oral Antiviral NV-387 - citybuzz -
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire
NNVC Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentEarnings Expansion Phase - newsline.com
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatmentwith Superior Oral Administration and Escape Resistance Features Over Antibodies - ACCESS Newswire
NanoViricides pushes chewable Ebola drug trial as Congo outbreak escalates - Stock Titan
NanoViricides Files for $50 Million Mixed Shelf Offering - Moomoo
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides (NNVC) Edges Lower Within Narrow Trading RangePre-Earnings Momentum - newsline.com
NanoViricides (NNVC) Slides 3.6% as Selling Pressure IntensifiesInstitutional Buy Signals - The Legal Advocate
NanoViricides (NNVC) Retreats 4.3%, Nears Critical Support at $1.69AAII Bullish - thelegaladvocate.com
Ebola Global Health Emergency Needs a Broad-Spectrum DrugNV-387 is a Strong Potential Candidate, Says NanoViricides - ACCESS Newswire
NNVC Q1 2026 Earnings: EPS Surpasses Expectations Amid Ongoing Development EffortsEPS Surprise History - newsline.com
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
Nanoviricides(NNVC) Stock Options Chain | Quotes & News - Moomoo
NanoViricides (NNVC) Surges 15.9% as Speculative Buying Drives Shares Above $1.75MA Cross Alert - The Legal Advocate
NanoViricides (NNVC) Surges 13.6% as Stock Approaches Key ResistanceSwing Trade Setups - The Legal Advocate
NNVC Stock Gains Attention As NV-387 Targets Ebola And Measles - StocksToTrade
NNVC Stock Draws Traders As NV-387 Targets Ebola, Measles - timothysykes.com
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides - ACCESS Newswire
Contact | Statesman-Examiner - FinancialContent
Rare Ebola strain has no treatment; NanoViricides lines up oral NV-387 - Stock Titan
NanoViricides Inc. (NNVC) Q1 2026 Earnings: Narrower Loss Drives Positive Stock ReactionProfit Guidance Range - newsline.com
Shelton biotech NanoViricides raises $2M in stock offering - Hartford Business Journal
A. G. P. Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Highlights NV-387 Strategy for Ebola Outbreak - TipRanks
NanoViricides Completes $2 Million Registered Direct Offering - TipRanks
NanoViricides Raises $2 Million in Registered Direct Offering With Common and Pre-Funded Warrants - TradingView
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug - citybuzz -
NanoViricides closes $2M direct offering - Yahoo! Finance Canada
NanoViricides, Inc - Reuters
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering - PharmiWeb.com
Antiviral developer NanoViricides secures $2M from single institutional investor - Stock Titan
NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak - citybuzz -
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
Ebola outbreak renews focus on broad-spectrum antivirals - EMJ
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak - Yahoo! Finance Canada
New Ebola strain has no treatment — NanoViricides highlights oral NV-387 - Stock Titan
NanoViricides Prices $2 Million Registered Direct Offering - citybuzz -
NanoViricides Advances NV-387 Toward Phase II Trials for MPox in DRC, Expands Orphan Drug Strategy - citybuzz -
NanoViricides to raise $2M in registered direct offering - Yahoo! Finance Canada
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering - ACCESS Newswire
Clinical-stage antiviral firm NanoViricides prices $2M stock-and-warrant deal - Stock Titan
NanoViricides, Inc. Has Filed its Quarterly ReportNV-387 Advancing for Phase II - Lelezard
Broad antiviral NV-387 drug candidate targets measles, mpox, smallpox - Stock Titan
NANOVIRICIDES, INC. 3Q FY2026: Net loss $(1.99M), EPS $(0.09) — 10-Q Summary - TradingView
NanoViricides: Fiscal Q3 Earnings Snapshot - marketscreener.com
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
NNVC Stock Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NanoViricides Inc (NNVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):